The pharmaceutical industry has increasingly taken aim at the program for growing costs, but is that accurate? American Hospital Association analysts offer this perspective.
In theory, patients should benefit from drug price discounts negotiated between drug companies and insurers. In reality, they don’t, and a potential solution is stalled in Congress.